A Common Drug Shows Stunning Promise in COVID Fight, and Beyond

A broader findings of an international study has surprised even seasoned researchers. Nearly 500 COVID-19 patients across six countries were enrolled in a test exercise, and results show that those who inhaled heparin were half as likely to require ventilation and had a significantly lower risk of death compared to patients who received standard care.

Maria Alvarez 62-year-old was admitted to a Madrid hospital in the thick of the pandemic’s third wave, her family braced for the worst. Breathless and exhausted, she was placed on oxygen and told her condition might soon require mechanical ventilation. But doctors offered her a chance to join a clinical trial using an unusual therapy: inhaled heparin, a medication more commonly associated with blood thinning injections after surgery. Within days, her breathing improved. She never needed a ventilator, and she walked out of the hospital weeks later.

The treatment, published in eClinicalMedicine and presented at the European Respiratory Society Congress, offers new hope not just against COVID but also for other respiratory infections like influenza, pneumonia and RSV. Researchers say the drug’s properties -anticoagulant, anti-inflammatory and pan-antiviral, make it uniquely suited for lung-targeted delivery. By being inhaled rather than injected, the medicine acts directly where it is most needed. The potential impact is enormous. In countries where intensive care beds are scarce and ventilators are limited, a treatment that reduces the need for mechanical support could ease the emotional and financial toll of prolonged hospital stays. Professor John Fraser, one of the study’s lead investigators said “what struck us most was the accessibility of this option. Heparin is inexpensive, widely available and easy to use, even in low-income settings”.